The ideal treatment of tumours should be able to eliminate cancer cells selectively, something that unfortunately is not achieved with most conventional treatments. For this reason it is thought that the immune system can be used in tumour therapy as a highly selective tool. They are produced in mice.
One of the treatments is the use of monoclonal antibodies (mAbs) directed against tumour-specific antigens such as CD2, CD33 or CD52 (lymphomas) or EGFR (breast cancer).
They are not enough to stop tumour development, because tumours have evasion mechanisms. Tumours usually receive surgical treatment first, accompanied by chemotherapy or radiotherapy, but these treatments are beginning to be replaced by biological therapy, whose main problem is that it is very expensive.

Main antitumour strategies:
- The antibodies used can be naked, carrying nothing conjugated, which activates complement and NK cells, producing lysis of tumour cells.
- If we conjugate it with substances such as ricin, the toxicity of the tumour is reduced and the body is not harmed.
- Cellular radiotherapy: combination with a radioactive isotope.
- Antibodies with enzymes and substances that degrade the tumour if it comes into contact with the enzyme.
- Combination with an enzyme. It converts a drug or prodrug into an active drug → this is the one that affects the rest of the cells least.
- Ab that recognise two substances, that is, they are bispecific: they attract antitumour cells to the tumour's surroundings.
These antibodies have 3 limitations:
- Poor accessibility to solid tumours
- Tumour escape (selection of variants lacking the antigen recognised by the mAb).
- Interspecies incompatibility (being murine, they can be rejected).
Several solutions have been found to these problems:
- On the one hand, they have been humanised, generating chimeras with the human Fc portion, which facilitates their tolerance and function in vivo via FcR while guaranteeing their specificity.
- On the other, they have been coupled to other mAbs that attract and activate cytolytic or helper cells (CD3+, CD2+ or CD16+) specifically at the tumour: these are bispecific mAbs.
- Finally, they are given their own cytostatic capacity in the form of immunotoxins, since some antibodies do not kill the target cell to which they bind. Immunotoxins are antibodies linked to modified cellular toxins (for example, diphtheria toxin or ricin), to radioactive isotopes (yttrium) or to enzymes that activate cytotoxic drugs. They will attack only the cell that carries the tumour antigen.